Skip to main content

Hikma Pharmaceuticals Plc Value Stock - Dividend - Research Selection

Hikma Pharmaceuticals Plc


Market price date: 12.08.2022
Market price: 19,41 USD

Hikma Pharmaceuticals Plc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 04-03-2022
Cash flow
Net operating cash flow 638.000.000
Capital Expenditures -145.000.000
Free cash flow 493.000.000
Balance sheet
Total Equity 2.453.000.000
Liabilities & Shareholders equity 4.372.000.000
Income statement
Net income 421.000.000
Eps (diluted) 1,807
Diluted shares outstanding 233.000.000
Net sales/revenue 2.553.000.000

Fundamental ratios calculated on: 12-08-2022

Key figures 12-08-2022
Cash flow
P/C 7,09
P/FC 9,17
Balance sheet
Income statement
Div. Yield2,68%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization4.522.529.792,00 USD
CountryUnited Kingdom
IndicesFTSE 100,STOXX EUROPE 600
Raw Data SourceIFRS in Millionen USD
Stock Split

Description of the company

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Hikma Pharmaceuticals Plc (HKMPF) 2022 Interim Results - Earnings Call Transcript

Hikma Pharmaceuticals Plc. (OTCPK:HKMPF) 2022 Interim Results August 04, 2022 05:30 AM ET Company Participants Said Darwazah - Executive Chairman & CEO Khalid Nabilsi - CFO Conference...

Hikma Pharmaceuticals PLC 2022 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2022 Q2 earnings call.

European markets muted; big Bank of England hike expected; Lufthansa up 5%

European stocks were slightly higher on Thursday as uncertainty returned following gains in the previous session.

Stocks making the biggest moves midday: Bausch Health, Meta, Comcast, Qualcomm and more

These are the stocks posting the largest moves in midday trading.

Comcast earnings beat Wall Street's estimates, reports flat broadband subscribers

CNBC's 'Squawk Box' team breaks down the latest earnings results from Comcast, which beat analysts' expectations on the top and bottom lines.

Stocks making the biggest moves in the premarket: Stanley Black & Decker, Southwest Airlines, Harley-Davidson and more

The stocks making the biggest moves in premarket trading include Stanley Black & Decker, Southwest Airlines, Harley-Davidson, and more.

WWE at crossroads as Vince McMahon's retirement and scandals heighten sale speculation

WWE can either move forward with sale discussions or take the business in new creative directions as Vince McMahon retires from his executive roles.

Sesame Solar is selling mobile disaster relief units powered entirely by clean energy

Sesame sells the systems for anywhere from $100,000 to $300,000, or more for larger installations like a full medical clinic.

Markets face what could be the most important week of summer with Fed, earnings and economic data

There's a head spinning amount of news for markets to navigate in the week ahead, the biggest of which will be the Federal Reserve's mid-week meeting.

Hikma price target lowered to 2,250 GBp from 2,500 GBp at Barclays

Barclays analyst Emily Fi... HKMPF